Updates are available Correction dated 2023-04-08
Click to view Correction: https://doi.org/10.1186/s12933-023-01813-8
-
Authors
Tynjälä, Anniina http://orcid.org/0000-0002-3913-5813
Harjutsalo, Valma http://orcid.org/0000-0003-3568-9779
Jansson Sigfrids, Fanny http://orcid.org/0000-0002-1192-348X
Groop, Per-Henrik http://orcid.org/0000-0003-4055-6954
Gordin, Daniel http://orcid.org/0000-0003-1494-8292
,
-
Funding
Funding for this research was provided by:
Biomedicum Helsinki-säätiö
Suomen Lääketieteen Säätiö
Finska Läkaresällskapet
University of Helsinki including Helsinki University Central Hospital
- License Information
-
More Information
Article History
Received: 5 December 2022
Accepted: 13 February 2023
First Online: 4 March 2023
Change Date: 8 April 2023
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1186/s12933-023-01813-8
Declarations
:
: The study protocol was approved by the Helsinki and Uusimaa Hospital District Ethics Committee, and the study was performed in accordance with the Declaration of Helsinki. Written informed consent was obtained from each participant.
: Not applicable.
: P–H.G. is an advisory board member of AbbVie, Astellas, AstraZeneca, Bayer, Boehringer Ingelheim, Eli Lilly, Janssen, Medscape, MSD, Mundipharma, Nestlé, Novartis, Novo Nordisk, and Sanofi, and has received lecture honoraria from Astellas, Astra Zeneca, Bayer, Boehringer Ingelheim, Eli Lilly, Elo Water, Genzyme, Medscape, MSD, Mundipharma, Novartis, Novo Nordisk, Sanofi and SCIARC. D.G. is an advisory board member of AstraZeneca, Bayer and Boehringer Ingelheim, and has received lecture or advisory honoraria from AstraZeneca, Bayer, Boehringer Ingelheim, Delta Medical Communications, EASD e-Learning, Finnish Association for Vascular Surgery, Finnish Kidney and Liver Foundation, and Finnish Nephrology Association. The other authors declared no competing interest.
